1. What’s happening
At SXSW 2026 this month, panelists highlighted how patients are increasingly turning to AI tools and online communities like Reddit to seek health information.
- According to the panelists, health content on Reddit alone saw 11.5 billion views in 2025, and HCPs are consistently using AI tools, with 40% of U.S. doctors using platforms like OpenEvidence daily.
- At the same time, platforms are introducing new trust mechanisms. For example, Reddit has begun incorporating verified contributors and moderators to improve the credibility of health information shared in communities.
2. What’s the big deal
Patients are frequently not waiting for the healthcare system to guide them. They’re actively researching, validating, and forming opinions upstream of care.
- They’re asking questions in ChatGPT, Google, and social media platforms; seeking peer validation and lived experiences in community forums like Reddit; and forming perceptions before treatment decisions are made.
- This reinforces a growing disconnect in how the industry understands the patient journey, which is still built around linear claims data within the healthcare system: HCP visit → testing → diagnosis → treatment → Rx
3. What’s at stake
As patients increasingly turn to AI and online communities as their first source of truth, life sciences companies risk losing influence over the earliest and most formative moments in the patient journey.
- Treatment perceptions may be shaped before HCP interaction, limiting the impact of traditional promotion and education. Misinformation or incomplete narratives could fill the gap, especially in unmoderated or weakly governed environments.
- Brand differentiation may erode if AI intermediaries standardize how therapies are presented.
- Commercial models could become reactive and respond to demand that has already been shaped elsewhere.
4. What it means for commercial execs
“Patients are signaling their needs continuously outside the healthcare system and in environments that require new trust frameworks,” observes Beghou Partner Sonam Dubey. “This shift pushes life sciences companies toward a fundamentally different commercialization mindset.”
- That mindset shift may entail engaging earlier in the journey when patients are forming beliefs and preferences, and to identify "hand-raising moments" when patients actively seek information, such as AI queries, social posts, and search behavior, explains Dubey, versus relying on retrospective data like claims and ‘scripts.
- At this earlier stage, pharma needs to deliver empathetic, context-aware content that reflects emotional and informational needs, while also translating research into better patient experience design and embedding trust guardrails into that engagement, she advises.
5. What’s next
-
Technology is changing more than how information is delivered. It’s changing where the patient journey begins, how it’s shaped, and who is responsible for its integrity.
- If patients increasingly start their journey in AI interfaces and online communities, then traditional claims or prescription data become lagging indicators, and commercialization strategies need to go beyond merely tracking behavior.
- For pharma, this represents a shift from services to experiences, from meeting expectations to anticipating needs, and from information delivery to trusted guidance (in places where patients are seeking that guidance).